(IN BRIEF) Sanofi has secured European Commission approval for Sarclisa® subcutaneous administration in combination with standard-of-care regimens for multiple myeloma, covering all indications already approved for the intravenous version of the therapy in the EU. The approval makes Sarclisa the … Read the full press release →
Posted in Business, European Union, France, Healthcare, Marketing, Pharma & Biotech, Science, Technology
Tagged anti-CD38 monoclonal antibody, anticancer therapy, biologic therapies, bortezomib, cancer care, carfilzomib, CirCLIQ OBI, Committee for Medicinal Products for Human Use, dexamethasone, Enable Injections, enFuse platform, European Commission, European Commission Approves Sanofi’s Sarclisa Subcutaneous Across Existing EU Multiple Myeloma Indications, European Medicines Agency, European Union, Healthcare Innovation, home administration, IRAKLIA phase 3 study, isatuximab, IZALCO phase 2 study, lenalidomide, MM, Mohamad Mohty, Multiple Myeloma, NCT05405166, NCT05704049, newly diagnosed multiple myeloma, Olivier Nataf, on-body injector, oncology, outpatient treatment, patient-centered care, pomalidomide, relapsed and refractory multiple myeloma, Saint-Antoine Hospital, Sanofi, Sanofi Advances Multiple Myeloma Care in Europe with First Anticancer Therapy Administered via On-Body Injector, Sanofi Secures EU Approval for Sarclisa Subcutaneous as First Anticancer Therapy Delivered Through an On-Body Injector, Sarclisa, Sarclisa IV, Sarclisa subcutaneous, Sarclisa Subcutaneous Approved in the EU as Sanofi Expands Flexible Treatment Options for Multiple Myeloma Patients, Sorbonne University, subcutaneous administration
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
